COMMUNIQUÉS West-GlobeNewswire

Nyxoah Reports First Quarter 2026 Financial and Operating Results
12/05/2026
REGULATED INFORMATION Nyxoah Reports First Quarter 2026 Financial and Operating Results Strong Genio launch in the U.S. drove 25% sequential quarterly U.S. revenue growth Continued clarity around HGNS and Genio [...]
TELA Bio Reports First Quarter 2026 Financial Results
12/05/2026
MALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial [...]
Jushi Holdings Inc. Reports First Quarter 2026 Financial Results
12/05/2026
Revenue of $66.4 million , Up 4% Year-over-Year, Driven by Strong Wholesale Growth and Benefits from Retail Expansion Gross Profit Margin Expanded 460 bps Year-Over-Year to 45.0% , Reflecting Improved Operational [...]
Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference
12/05/2026
SAN JOSE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and [...]
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
12/05/2026
C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial Outside North America for Treatment of HCV on Track to [...]
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
12/05/2026
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of [...]
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
12/05/2026
Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026 Timeline for submission of NDA of deucrictibant IR for the on-demand treatment of HAE [...]
Biomea Fusion to Participate at Upcoming Investor Conferences
12/05/2026
SAN CARLOS, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that management will participate in [...]
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference
12/05/2026
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms [...]
Lifecore Biomedical to Participate at CDMO Live Europe
12/05/2026
CHASKA, Minn., May 12, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that [...]
Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates
12/05/2026
Next anticipated Revita ® clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026 and 1-year randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026 Early Q4 2026 timing for topline 6-month [...]
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
12/05/2026
Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soon HOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb function) and all [...]
Nyxoah Publie ses Résultats Financiers et Opérationnels du Premier Trimestre 2026
12/05/2026
INFORMATIONS RÉGLEMENTÉES Nyxoah Publie ses Résultats Financiers et Opérationnels du Premier Trimestre 2026 Le lancement réussi de Genio aux États-Unis génère une croissance trimestrielle séquentielle de 25 % du chiffre [...]
LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
12/05/2026
Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression Published results from the Phase 2 NOVA-1 trial of LB-102 in [...]
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs
12/05/2026
Data presented at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting SEATTLE, May 12, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible [...]
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
12/05/2026
First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 Cash balance of $23.9 million as of March 31, 2026 anticipated to fund operations into [...]
Surrozen to Present at Upcoming Healthcare Investor Conference
12/05/2026
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling [...]
Lumexa Imaging Advances Growth Strategy by Adding Four New Imaging Centers
12/05/2026
Expansion across the Southeast and Mid-Atlantic includes entry into Pennsylvania through joint venture with University of Pittsburgh Medical Center (UPMC) RALEIGH, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging ( [...]
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
12/05/2026
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today [...]

Pages